Now treating — Lu‑177 · Ac‑225 · Tb‑161 · Y‑90

Nuclear Medicine
Therapy in India.

India's first physician-led nuclear medicine and theranostics practice. Clarity, care, and transparent pricing — delivered at Fortis Memorial Research Institute, Sector 44, Gurugram.

Explore services WhatsApp +91 8700 668 431
30+
Years in nuclear medicine, Dr. Sen
8
Radionuclides administered on site
72h
Quote turnaround, in writing
Dr. Ishita B. Sen, Director, Nuclear Medicine, Fortis Memorial Research Institute
Dr. Ishita B. Sen
Director · Nuclear Medicine, FMRI
Dr. Dharmender Malik
Senior Consultant, Nuclear Medicine, FMRI
Practising
Transparent pricing
INR and USD published in the open. Quote in writing within 24 working hours.
Direct line to the physician
No tourism agents, no aggregators. You speak to Dr. Sen's team.
Dosimetry-led dosing
Doses based on individual weight, prior treatment and renal function. Not formulas.
Practising at FMRI
JCI-accredited Fortis Memorial Research Institute, Sector 44, Gurugram.
A practice, not a clinic

Three decades of nuclear medicine, delivered with the rigour of a research department and the warmth of a family practice.

"In India, the patients who need radioligand therapy the most are too often routed through tourism agents and aggregator platforms, with no direct line to the physician actually treating them. That is not how cancer should be looked after."

At Fortis Memorial Research Institute in Gurugram, we run a single, vertically integrated practice — from the first PET-CT scan through to the final cycle of Lu‑177 or Ac‑225, the same team that decides on therapy administers it, follows up on it, and answers the questions that come at 11 p.m.

For international patients, that means transparent pricing in INR and USD, dosimetry-led dosing, and a clinical lead on WhatsApp. For Indian patients, it means access to therapies typically reserved for the world's leading academic centres — delivered at scale, and at price points your family can plan for.

Dr. Ishita B. Sen
Dr. Ishita B. Sen
Founder · Director, Nuclear Medicine, FMRI
What we do

Five doors into the practice. One team behind each.

Whether you are booking a first PET-CT scan or coming to us for fourth-line radioligand therapy, the same physicians read your imaging and prescribe your cycles. There is no handoff.

Theranostic radionuclide therapy
Theranostic therapy

Targeted radionuclide therapy — eight isotopes, one centre.

Lu‑177 PSMA, Ac‑225 PSMA, Lu‑177 DOTATATE (PRRT), Ac‑225 α-PRRT, Tb‑161, ¹³¹I-mIBG, Y‑90 TARE, Ra‑223 — delivered cycle‑by‑cycle in our day-care and twin-share wards, with dosimetry-led dosing and full post-treatment imaging.

View therapies
PET-CT scan booking at FMRI Gurugram
Diagnostics

PET-CT & nuclear scans at FMRI.

35+ scan types on Siemens Biograph Vision — PSMA, DOTATATE, FDG, Amyloid, Exendin — bookable at FMRI Sector 44 with same-week appointments and physician interpretation.

Book a scan
Online consultation with Dr. Sen
Telehealth

Online consultation

20-minute Google Meet with Dr. Sen. For patients in India on the consultation date. NMC Telemedicine 2020 compliant.

Book a slot
PET-CT second read service
Global · 72h

PET-CT second read

Expert imaging review for patients worldwide. 72-hour SLA. ₹ 2,500 / USD 100. Read by Dr. Sen personally.

Submit a study
For referring physicians and clinical partnerships
For physicians

Clinical partnerships

Bilateral case discussions, referral coordination, and shared dosimetry for partner oncology and urology teams.

Begin a referral
The Theranostics Engine

Eight radionuclides. One disciplined practice.

From the well-established Lu‑177 to the emerging Tb‑161, we administer every therapeutic radionuclide approved or available for compassionate use in India. Dose escalation is dosimetry-led; cadence is biology-led.

Lutetium-177 PSMA therapy
β Beta · FMRI co-authored
177Lu
PSMA therapy
Prostate cancer · mCRPC
Actinium-225 PSMA therapy
α Alpha · FMRI co-authored
225Ac
PSMA therapy
PSMA+ disease · salvage line
Lu-177 DOTATATE PRRT
β Beta
177Lu
DOTATATE (PRRT)
Neuroendocrine tumours
Ac-225 alpha PRRT
α Alpha
225Ac
α-PRRT
Refractory NETs
Tb-161 PSMA therapy
β + Auger · Emerging
161Tb
PSMA therapy
Micro-metastatic disease
I-131 mIBG therapy
β Beta
131I
mIBG
Neuroblastoma · pheochromocytoma
Y-90 TARE liver-directed therapy
β Beta · Liver-directed
90Y
TARE
HCC · metastatic liver disease
α Alpha · Bone-targeted
223Ra
dichloride
Bone-only mCRPC
Watch & listen

In Dr. Sen's own words — the practice, on camera.

A growing library of clinical explainers, patient-facing primers, and conference talks. Subscribe on YouTube for new episodes.

Unlock the science behind nuclear medicine therapy.

Featured interview — Dr. Ishita B. Sen, Senior Director, Nuclear Medicine, FMRI Gurugram

YouTube channel
Nuclear medicine vs radiology
Explainer · 4 min
Nuclear medicine unveiled — how it differs from radiology.
Biograph Vision PET-CT technology
Technology · 5 min
Biograph Vision™ — reshaping cancer care at FMRI.
Radioisotope therapy explained
Clinical · 8 min
Radioisotope therapy — best explained, for patients.
Department of Nuclear Medicine, FMRI Sector 44
The Care Centre
Fortis Memorial Research Institute
Lower Ground Floor, Department of Nuclear Medicine · Sector 44, Gurugram, Haryana 122002
Where the work happens

Practising inside one of South Asia's most equipped nuclear medicine departments.

3
Siemens Biograph PET-CT scanners on the floor
5
Shielded therapy rooms for radionuclide administration
JCI-accredited tertiary care: FMRI is a 1,000+ bed multi-specialty hospital, repeatedly ranked among India's top private hospitals.
Automated radiopharmaceutical dispensing: reducing radiation exposure for staff and improving dose precision for patients.
35–45 minutes from IGI Airport: via the Dwarka Expressway. International patient coordination available end-to-end.
On-floor multidisciplinary review: urology, medical oncology, radiation oncology and interventional radiology in the same building.
Lead physicians

The team that decides on therapy is the team that delivers it.

Dr. Ishita B. Sen Founder · Principal Director

Dr. Ishita B. Sen

MBBS · DRM · DNB (Nuclear Medicine)
Director & Head, Department of Nuclear Medicine and Molecular Imaging, Fortis Memorial Research Institute

30+ years in nuclear medicine. Visiting fellowships at Memorial Sloan Kettering Cancer Centre, New York and the University of Marburg, Germany. Former President, Association of Nuclear Medicine Physicians of India. Co-author on published Lu‑177 and Ac‑225 protocols.

Nuclear Oncology Radionuclide Therapy PET-Guided Procedures Theranostics
Full profile
Dr. Dharmender Malik Co-Founder · Senior Consultant

Dr. Dharmender Malik

MBBS · MD (Nuclear Medicine)
Senior Consultant, Department of Nuclear Medicine, Fortis Memorial Research Institute

Specialist in radionuclide therapy administration, post-therapy imaging, dosimetry, and PSMA/PRRT cycle planning. Co-leads the centre's clinical follow-up programme and patient-side communication for international cases.

Radioligand Therapy Dosimetry Post-Therapy Imaging PRRT
Full profile
Therapy calendar

Real cadence, real slots.

Lu‑177 cycles run Fridays. Y‑90 TARE on Wednesdays. Ac‑225 and Tb‑161 alternate fortnights. mIBG and Ra‑223 are scheduled by clinical priority. The next six weeks below.

Lu‑177 (PSMA + PRRT) Ac‑225 (PSMA + α-PRRT) Tb‑161 PSMA Y‑90 TARE ¹³¹I-mIBG Ra‑223
Week 21· May
19–25 May
Lu‑177 PSMA
Fri 22 May
Y‑90 TARE
Wed 20 May
Ac‑225 PSMA
Fri 22 May · fortnight
Reserve →
Week 22· May
26 May–1 Jun
Lu‑177 DOTATATE
Fri 29 May
Y‑90 TARE
Wed 27 May
Tb‑161 PSMA
Fri 29 May · fortnight
Reserve →
Week 23· Jun
2–8 Jun
Lu‑177 PSMA
Fri 5 Jun
Y‑90 TARE
Wed 3 Jun
Ac‑225 α-PRRT
Fri 5 Jun · fortnight
Reserve →
Week 24· Jun
9–15 Jun
Lu‑177 DOTATATE
Fri 12 Jun
Y‑90 TARE
Wed 10 Jun
Tb‑161 PSMA
Fri 12 Jun · fortnight
Reserve →
Week 25· Jun
16–22 Jun
Lu‑177 PSMA
Fri 19 Jun
Y‑90 TARE
Wed 17 Jun
Ac‑225 PSMA
Fri 19 Jun · fortnight
Reserve →
Week 26· Jun
23–29 Jun
Lu‑177 DOTATATE
Fri 26 Jun
Y‑90 TARE
Wed 24 Jun
Tb‑161 PSMA
Fri 26 Jun · fortnight
Reserve →

¹³¹I-mIBG and Ra‑223 are scheduled by clinical priority. Daily slots (Mon–Sat). Please call ahead.

Pricing & doses

No commission. No tourism markup. No hidden ranges.

Indicative cycle pricing, in the open. Indian patients pay the Indian rate; international patients pay a rate that includes our end-to-end facilitation. We publish the numbers because aggregators won't.

Therapy Typical dose / cycle Indian patient International patient
177Lu PSMA (Indian-source)
Beta therapy		 7.4 GBq ₹ 75,000 / cycle
≈ USD 833		 German-source only
177Lu PSMA (German-source)
Beta therapy		 7.4 GBq ~ ₹ 5,85,000 / cycle
USD 6,500		 ₹ 6,50,000 / cycle
USD 7,222
177Lu DOTATATE (PRRT)
Beta therapy · NETs		 7.4 GBq On request ₹ 5,70,000 / cycle
USD 6,333
225Ac PSMA
Alpha therapy		 100 kBq/kg ~ ₹ 13,05,000 / cycle
USD 14,500		 ₹ 15,22,500 / cycle
USD 16,917
225Ac DOTATATE (α-PRRT)
Alpha therapy · NETs		 100 kBq/kg On request ₹ 15,22,500 / cycle
USD 16,917
161Tb PSMA
Emerging · Auger + beta		 7.4 GBq ~ ₹ 5,17,000 / cycle
USD 5,747		 ₹ 7,50,000 / cycle
USD 8,333
90Y TARE
Liver-directed		 3.0 GBq On request On request
223Ra dichloride
Bone-targeted alpha		 50 kBq/kg On request On request
131I mIBG
Neuroblastoma · refractory pheo		 100–200 mCi On request On request
★ Please read

Figures are indicative ranges, not quotes, presented at 1 USD = ₹ 90. They represent the therapy fee only and exclude diagnostic imaging, concomitant medication, room category supplements and any inpatient stay charges levied by FMRI.

Typical doses are also indicative. We administer doses based on individual dosimetry, body weight, prior treatment, renal and marrow function, and tumour burden — well-titrated, clinically meaningful doses are a deliberate practice philosophy and one of the reasons response rates at our centre have been consistent.

Want the real number for your case?

Send Dr. Sen's team a short note — therapy of interest, indication, and body weight if known — and you'll have a written quote within 24 working hours.

WhatsApp the team +91 8700 668 431 · fastest route
Email Dr. Sen's team info@nuclearmedicinetherapy.in
Second Read Service

A second pair of eyes on your PET-CT.

For patients and clinicians anywhere in the world. Upload the DICOM, share the clinical context, and have a senior nuclear medicine physician at FMRI re-read the study from scratch — not as a rubber stamp, but as a fresh interpretation.

72h
Report turnaround
₹ 2,500
Indian patients
USD 100
International patients
Read personally by Dr. Ishita B. Sen — not a junior or a residency programme.
A 1–2 page structured report with findings, impression, and recommended next steps.
DICOM accepted; we work with PSMA, DOTATATE, FDG, Amyloid and Exendin studies.
Available globally — secondread@nuclearmedicinetherapy.in is monitored 7 days a week.
Submit a study Email secondread@
PET-CT second read service
“Read by the physician who treats — not the algorithm who annotates.”
For referring physicians

Sending us a patient? Here is how we work.

We have refined a referral protocol over a decade of international and domestic case-flow. Cleaner inbound. Faster turnaround. No mystery on dose or rationale.

01
Bilateral case discussion15–30 min consultant-to-consultant call before the patient is moved. Imaging, prior lines, dosimetry questions on the same table.
02
Structured referral documentationSigned referral letter, prior imaging on DICOM, prior pathology, current labs. We send back a written treatment plan within 48 hours.
03
Shared follow-up loopPost-therapy imaging and labs are sent back to the referring physician within 7 days of every cycle. The patient stays your patient.
Begin a referral WhatsApp clinical team
FAQ

Questions we hear most often.

What is theranostics, and how is it different from chemotherapy?

Theranostics couples a diagnostic radiotracer (e.g., ⁸⁸Ga-PSMA-11 or DOTATATE-PET) with a therapeutic radiopharmaceutical (e.g., Lu‑177-PSMA-617 or Lu‑177-DOTATATE) that bind the same molecular target on the tumour. Unlike chemotherapy, which acts on all rapidly dividing cells, a theranostic agent delivers radiation only to cells expressing the target receptor — sparing healthy tissue.

How much does lutetium-177 cost in India?

At our centre, Lu‑177 PSMA (Indian-source) is ₹ 75,000 per cycle for Indian patients. Lu‑177 PSMA (German-source, Pluvicto-equivalent) is approximately ₹ 5,85,000 per cycle for Indian patients and ₹ 6,50,000 (USD 7,222) per cycle for international patients. These are therapy fees only and exclude diagnostic imaging, room category, and inpatient stay charges levied separately by FMRI.

How effective is lutetium for prostate cancer?

In published phase 3 evidence (the VISION trial), Lu‑177 PSMA-617 extended overall survival in metastatic castration-resistant prostate cancer (mCRPC) by approximately 4 months versus standard of care and significantly delayed radiographic progression. At our centre, response is measured patient-by-patient using PSA kinetics and post-therapy SPECT/PET imaging; we recommend a formal eligibility review before initiating therapy.

How long does lutetium extend life?

The VISION trial reported a median overall survival of 15.3 months with Lu‑177 PSMA-617 plus standard of care, compared to 11.3 months with standard of care alone — a survival benefit of approximately 4 months in heavily pre-treated mCRPC patients. Individual outcomes vary considerably with disease burden, prior treatment lines, and dosimetry-led dose optimisation. We discuss your specific expected benefit during the consultation.

Who is eligible for Lu‑177 PSMA therapy?

Patients with metastatic castration-resistant prostate cancer (mCRPC) who have demonstrated PSMA-positive disease on a PSMA-PET scan and who meet renal, hepatic and marrow function thresholds. We assess each candidate individually — line of treatment, prior chemotherapy and disease burden all matter. A formal eligibility review is included in our online consultation.

How much does PRRT cost in India at your centre?

Lu‑177 DOTATATE (beta PRRT) for international patients is ₹ 5,70,000 (approx. USD 6,333) per cycle. Indian-patient pricing is on request. Ac‑225 α-PRRT for international patients is ₹ 15,22,500 (approx. USD 16,917) per cycle. The published figures cover the therapy itself; diagnostic imaging, room category and concomitant medication are billed separately by FMRI.

What is the difference between Lu‑177 and Ac‑225?

Both are PSMA-targeted radioligand therapies, but they emit different particles. Lu‑177 emits beta particles (path length ~2 mm), suited to larger disease volumes. Ac‑225 emits alpha particles (path length ~50–100 μm), with substantially higher linear energy transfer — useful for micro-metastatic disease and patients who have progressed on Lu‑177. We use both at our centre and choose between them based on disease pattern and prior response.

Where is the centre located and how do I reach it from IGI Airport?

Our clinical operations are at the Department of Nuclear Medicine, Lower Ground Floor, Fortis Memorial Research Institute, Sector 44, Gurugram, Haryana 122002. From IGI Airport, the drive is approximately 35–45 minutes via the Dwarka Expressway. Airport pickup can be arranged for international patients on request.

Does Dr. Sen take online consultations?

Yes. Dr. Sen offers 20-minute online consultations via Google Meet. The service is governed by the National Medical Commission (Telemedicine Practice) Regulations 2020 and is currently available to patients who are physically present in India on the date of the consultation. Every session is recorded and the recording link is shared with the patient.

Is the Second Read Service available outside India?

Yes. The Second Read Service is offered globally. Upload your PET-CT in DICOM format (or as a deidentified PDF report with images), share the relevant clinical context, and Dr. Sen will personally re-read the study and send back a structured 1–2 page report within 72 hours. International rate: USD 100 per study.

Let's begin

The next conversation is the next step.

Whether you are a patient looking for clarity, a caregiver navigating options, or a physician seeking a partner — reach out. We answer.

WhatsApp +91 8700 668 431 info@nuclearmedicinetherapy.in

Medical disclaimer All physicians and researchers profiled on this page hold appointments at the Department of Nuclear Medicine & Molecular Imaging, Fortis Memorial Research Institute, Gurugram. Theranostic Physicians Private Limited (TPPL) is the clinical practice entity through which they consult and treat patients. Treatment outcomes vary by individual case; clinical decisions are made on the basis of complete medical records, current imaging, and a multidisciplinary review.